Semaglutide Dosage Guide: Reported Ranges, Reconstitution & Half-Life

Semaglutide at a glance

What it is

A long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, approved as Ozempic, Wegovy and Rybelsus

Researched for

Type 2 diabetes, chronic weight management, and cardiovascular risk reduction

Commonly reported range

Label escalation 0.25 to 2.4 mg once weekly (Wegovy); maintenance 1.7 or 2.4 mg once weekly

Route reported

Subcutaneous injection once weekly (an oral tablet form also exists)

Reported frequency

Once weekly

Reported cycle

Label escalation raises the dose every 4 weeks toward the maintenance dose; treatment is ongoing, not cycled

Plasma half-life

Approximately 1 week (elimination half-life about 155 hours)

Regulatory status

FDA-approved and prescription-only. Research-market material is NOT the pharmacy product and is research use only

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

Semaglutide is an acylated analog of human GLP-1, an incretin hormone released from intestinal L-cells after eating. Substitutions at positions 8 and 34 make it resistant to degradation by dipeptidyl peptidase-4, and a C18 fatty-diacid chain attached via a linker promotes reversible albumin binding; together these give it a duration of action long enough for weekly dosing. At the GLP-1 receptor it is reported to enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, and slow gastric emptying. Because the insulin effect is glucose-dependent, the risk of hypoglycaemia from the drug alone is described as low, though it rises when combined with insulin or sulfonylureas. Receptors in hypothalamic and hindbrain appetite circuits are the reported basis of the reduction in appetite and energy intake that drives weight loss.

Researched effects

In clinical trials semaglutide has been associated with reduced HbA1c in type 2 diabetes, reduced appetite and energy intake, and substantial body-weight reduction - the STEP programme reported roughly 15% mean weight reduction at 68 weeks at the 2.4 mg dose in people with obesity, and the SELECT trial reported a reduction in major adverse cardiovascular events in people with established cardiovascular disease and overweight or obesity. These are reported trial findings in supervised populations, not guaranteed outcomes; individual results varied considerably, and weight regain after discontinuation has been reported. Nothing here is a promise of efficacy or a personal recommendation.

Dosage — reported ranges (overview)

The figures below describe the approved label and published trials, provided as educational context rather than as a recommendation. The Wegovy label uses a fixed escalation: 0.25 mg once weekly for 4 weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, each for 4 weeks, reaching a maintenance dose of 2.4 mg once weekly (1.7 mg is also an accepted maintenance dose where 2.4 mg is not tolerated). Ozempic for type 2 diabetes escalates similarly toward 1.0 or 2.0 mg weekly. The slow escalation exists specifically to limit gastrointestinal side effects, which are dose-related. This is a prescription medicine whose dose is selected and monitored by a clinician for an individual - the schedule above is what the label specifies, not what any particular person should take.

A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.

Reconstitution — bac-water math

Research-market semaglutide is supplied lyophilized, so reconstitution is a concentration calculation. Add bacteriostatic water to the vial and the concentration is the vial's total mg divided by the water volume in mL. On a U-100 insulin syringe, 100 units equals 1 mL, so units to draw = dose (mg) / concentration (mg/mL) x 100. Worked example: a 5 mg vial reconstituted with 2 mL of bacteriostatic water gives 2.5 mg/mL; a 0.25 mg example is then 0.25 / 2.5 = 0.1 mL, which is 10 units on a U-100 syringe. Because semaglutide amounts are small, the arithmetic is unforgiving - a decimal error here is a tenfold error in the amount drawn. This is concentration math only, not a personal dose. Add water slowly down the vial wall and swirl gently rather than shaking.

This is concentration math, not a dose recommendation.

Injection / administration basics

The approved label specifies subcutaneous injection once weekly into the abdomen, thigh or upper arm, rotating the site, on the same day each week. Approved products are supplied in pre-filled pens rather than as a powder requiring reconstitution. General handling concepts - sterile technique, site rotation, consistent weekly timing - are covered here as general information; the detailed workflow comes with All-Access Lifetime, which includes the printable protocol sheet and injection log for every compound. This is general educational information, not a personal administration protocol; semaglutide is a prescription medicine and a qualified professional should direct any actual use.

Half-life & frequency rationale

Semaglutide has an elimination half-life of approximately 155 hours, or about one week, which is the basis for once-weekly dosing. Steady state is reached after roughly 4 to 5 weeks of consistent weekly administration, which is also why the label escalates at 4-week intervals - each step is assessed near steady state rather than mid-accumulation. The long half-life means the drug persists for several weeks after the last dose.

Stacking — overview

In clinical development semaglutide has been formally combined with cagrilintide, an amylin analog, as CagriSema, where the two appetite pathways are reported to act additively. Community discussion also describes pairing GLP-1 agonists with compounds intended to preserve lean mass during weight loss, though this is not supported by approval-grade evidence. Combining a prescription GLP-1 with other agents is a clinical decision with real interaction risk, not a lifestyle choice; these reflect reported pairings, not recommendations.

For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.

Storage & handling

• Approved pre-filled pens are stored refrigerated at 2-8 C before first use and protected from light; consult the product label for in-use storage, which differs by product.
• Research-market lyophilized vials are typically stored refrigerated and protected from light; after reconstitution keep refrigerated at about 2-8 C, use within a few weeks, do not freeze and avoid shaking.

Evidence File

The Semaglutide Evidence File: 773 Registry Records, Seven Programme Codes, and the Trial the Market Has Not Caught Up With

Semaglutide is one of the most heavily trialled molecules in this catalog, which changes what an evidence file is for: not finding data, but auditing it. This file works from a complete ClinicalTrials.gov census pulled on the verification date, from the sponsor's own internal programme codes, and from the abstracts of the trials that produced the figures the market repeats. It reads the parts of the record that summaries skip - the terminated and withdrawn tail, the studies registered under codes no chemical registry lists, the large randomised result that did not go the way the field expected - and traces each circulating number back to the analysis that produced it.

• 773 registry records reviewed in a single census pull
• 7 Novo programme codes; only 2 appear in chemical registries
• 9 terminated, 14 withdrawn and 1 suspended record read line by line
• 5 circulating figures traced to the analysis that produced them

Sourcing File

The Semaglutide Sourcing File: Two Mass Fields One Dalton Apart, a Salt the FDA Calls a Different Drug, and Three Vials That Were 99 Percent Pure on Paper

Semaglutide is unusual on the research market: an approved pharmaceutical with a complete public chemical record, sold in a form the approved product never takes. That combination creates sourcing questions no generic peptide guide covers. This file anchors the compound to its authoritative chemical record, works out from that record what a genuine mass spectrum must look like and why one widely quoted mass field means something different from what certificates claim it means, computes net peptide content for each plausible counter-ion, maps the mislabelling modes a regulator has documented for this exact molecule, audits a specimen certificate line by line against its own numbers, and closes on the one published study in which someone bought this material without a prescription and put it through an analytical laboratory.

• 2 PubChem mass fields 1 Da apart that mean different things
• 6 mislabelling modes documented by FDA for this exact compound
• Net peptide computed for acetate, TFA and sodium counter-ion loads
• 3 test-purchased vials: 99 percent claimed on the label, far less found

Benefit & Outcome Review

Semaglutide Benefit and Outcome Review: Twelve Claims Graded Against What Was Actually Measured, In Whom, and For How Long

Unusually for anything in a peptide catalog, semaglutide's claims can be graded against randomised, placebo-controlled, event-driven trials with tens of thousands of participants. That changes the shape of an honest review: the verdicts here are mostly not unproven but proven in this population, at this dose, for this duration, by this margin. The value is in the qualifiers. Each claim below is set against the trial that tested it, the comparator arm's own result, the proportion who did not respond, and the population that was enrolled - plus the questions that have no answer yet, including one completed trial whose only public result sits in a registry field rather than in any journal.

• 12 marketed claims graded against the trials that tested them
• 1 claim tested at scale in 3808 people and not supported
• Placebo-arm results attached to every effect size quoted
• 1 completed trial whose result exists only in the registry

Guide FAQ

Quick answers about guide scope, access, and educational use context.